<DOC>
	<DOC>NCT00501267</DOC>
	<brief_summary>The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together</brief_summary>
	<brief_title>A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Solabegron</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Healthy adult males &amp; females ages 1865; Body weight &gt;50kg; BMI between 1932; Signed and dated informed consent; QTc Interval &lt;450 msec; Resting blood pressure &gt;140/90 mmHg or HR &gt;100 at screening; History of drug allergy or other allergy which, in the opinion of the PI, contraindicates their participation; Positive urine drug, alcohol or serum pregnancy test at screening and prior to dosing; Positive HIV, Hepatitis B, C at screening; use of medications (except acetaminophen)or vitamins or herbal supplements within 7 days or 5 half lives prior to dosing and during study; history of urinary retention, gastric retention, and other sever gastrointestinal motility conditions, uncontrolled narrowangle glaucoma or who are at risk for these conditions; history of chronic constipation and/or regular laxative use; donation of more than 500mL of blood within 56 days prior to dosing; clinically relevant abnormality identified during screening process or any medical condition or circumstance making the subject unsuitable for participation based on the Investigators assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>solabegron,</keyword>
	<keyword>oxybutynin,</keyword>
	<keyword>healthy adults,</keyword>
	<keyword>drug interaction</keyword>
</DOC>